The Wealth Company Large and Mid Cap Fund
Direct · GrowthAI Summary
The fund has outperformed the NIFTY 50 across all reported periods, with a 1Y CAGR of 4.15% versus the benchmark's 1.26%, though absolute returns remain modest. Alpha is positive at 1.28% over 1Y but turns negative over longer windows (e.g., -1.67% over 10Y), suggesting underperformance versus risk-adjusted expectations over time. SIP XIRR data is not available, so like-for-like comparison with the category average SIP XIRR of 16.54% (1Y) cannot be made.
Risk metrics indicate an exceptionally low drawdown profile, with a maximum drawdown of just -0.027%, a 2-day drawdown duration, and zero drawdown events exceeding 10%. A beta of 0.69 with a downside capture of only 57.91% versus the NIFTY 50 confirms strong downside protection. However, upside capture of 82.97% means the fund also participates less fully in market rallies, which is consistent with its modest absolute returns.
The portfolio holds 48 stocks with a well-diversified top 10, where the largest position (Radico Khaitan at 3.8%) is modestly sized. Sector exposure is spread across Pharmaceuticals (9.3%), Capital Markets (8.3%), Electrical Equipment (6.8%), Consumer Durables (6.2%), and Beverages (5.2%), avoiding heavy single-sector concentration. Holdings span defensive and cyclical areas, including Bajaj Auto, Dixon Technologies, Hindustan Aeronautics, and Coforge, providing balanced large and mid-cap exposure.
Direct comparison with category peers is limited because the fund's SIP XIRR is unavailable, while the category average SIP XIRR stands at 16.54% (1Y) and 17.73% (3Y). The fund's low beta and downside capture suggest a defensive positioning that may lag aggressive large and mid-cap peers in strong bull phases. With only calendar year 2026 data (4.6%) and a NAV of ₹10.5041, the fund appears very new, making consistency assessment premature.
This fund may suit conservative investors seeking large and mid-cap exposure with lower volatility, given its 0.69 beta and strong downside capture characteristics. A long-term horizon of 5-7 years or more is appropriate for this category, allowing mid-cap allocations to compound. Investors should be comfortable with the possibility of underperforming the broader market in strong rallies due to the 82.97% upside capture.
- Strong downside protection with downside capture of 57.91% and zero drawdown events exceeding 10%
- Outperformed the NIFTY 50 across all reported periods, including a 1Y CAGR of 4.15% versus 1.26% for the benchmark
- Zero expense ratio (0.0% TER) on the Direct plan, minimizing cost drag on returns
- Negative alpha over longer periods (e.g., -1.67% over 10Y), indicating underperformance on a risk-adjusted basis versus the benchmark
- Limited track record with only 2026 calendar year data (4.6%) and no SIP XIRR available, making performance evaluation against the category average (16.54% 1Y SIP XIRR) impossible
Generated on 08-09-2026, 2:58 AM. Verify before investing.
The largest peak-to-trough decline in the fund's NAV. Shows the worst-case loss an investor would have experienced at any point in the fund's history.
Not enough data to compute SIP returns.
Not enough data to compute rolling returns.
Compared against NIFTY 50
| Duration | Alpha | Beta | Upside Capture | Downside Capture | Fund CAGR | Bench CAGR |
|---|---|---|---|---|---|---|
| 1 Year | +1.28 | 0.69 | 83.0% | 57.9% | 4.2% | 1.3% |
| 3 Years | -0.91 | 0.69 | 83.0% | 57.9% | 1.4% | 0.4% |
| 5 Years | -1.34 | 0.69 | 83.0% | 57.9% | 0.8% | 0.3% |
| 7 Years | -1.54 | 0.69 | 83.0% | 57.9% | 0.6% | 0.2% |
| 10 Years | -1.67 | 0.69 | 83.0% | 57.9% | 0.4% | 0.1% |
| 12 Years | -1.72 | 0.69 | 83.0% | 57.9% | 0.3% | 0.1% |
| 15 Years | -1.78 | 0.69 | 83.0% | 57.9% | 0.3% | 0.1% |
| # | Stock | % of NAV |
|---|---|---|
| 1 | ICICI Bank Limited | 3.56% |
| 2 | Billionbrains Garage Ventures Ltd. | 2.85% |
| 3 | Multi Commodity Exchange of India Ltd. | 2.72% |
| 4 | Nippon Life India Asset Management Ltd | 2.63% |
| 5 | Bajaj Auto Limited | 2.50% |
| 6 | Bajaj Finance Limited | 2.47% |
| 7 | Aditya Infotech Limited | 2.47% |
| 8 | GlaxoSmithKline Pharmaceuticals Ltd | 2.38% |
| 9 | Jindal Saw Ltd | 2.36% |
| 10 | Divi's Laboratories Limited | 2.29% |